Skip to main content

Table 1 Case reports of cardiotoxicity with gemcitabine monotherapy

From: Gemcitabine-induced cardiomyopathy: a case report and review of the literature

Author Demography Dose of gemcitabine Duration of treatment Side effect History of CAD Timing Outcome Probability
Ozturk et al.[17] 59F with metastatic leiomyosarcoma 900mg/m2 8 days Coronary vasospasm Yes 30 minutes after infusion Survived. Gemcitabine therapy stopped Strong
Bdair et al . [18] 43F with metastatic NSCLC 1000mg/m2 7 weeks NSTEMI VT Yes 3 days after infusion Survived. Gemcitabine therapy stopped Weak
Kalapura et al . [19] 54M with metastatic pancreatic cancer 1900mg 5th cycle NSTEMI No CAD, no risk factors 6 hours after infusion Survived. Recurrent symptoms with 7th cycle Strong
Tayer-Shifman et al.[20] 67F with metastatic ductal carcinoma of breast 1000-1400mg/m2 3rd cycle SVT/AVNRT No CAD, no risk factors Hours after infusion Survived. Gemcitabine therapy stopped Strong
Santini et al.[21] 78M with pancreatic adenocarcinoma NK 1st cycle AF History of AF in the past 18-22 hours after the infusion Survived 6 total episodes of AF 18-22 hours after the infusion Strong
Ferrari et al.[22] 72F with metastatic lung adenocarcinoma 1200mg/m2 1st cycle AF No history of AF 18 hours after the infusion Survived 3 total episodes of AF each after 18 hours of infusion Strong
Ferrari et al.[22] 73F with NSCLC 1200mg/m2 3rd cycle AF No history of AF 12 hours after the infusion Survived. Gemcitabine stopped Strong
Tavil et al.[23] 65M with NSCLC 1200mg/m2 2nd cycle AF No history of AF 7 hours after the infusion Gemcitabine stopped Strong
Ciotti et al.[24] 70M with metastatic pancreatic adenocarcinoma NK 1st cycle AF No history of AF 6 days after the infusion AF recurred with further therapy Strong
Yajima et al.[25] 82F with advanced pancreatic carcinoma 16, 800mg-total dose Two years of treatment HF NK 2 years Gemcitabine stopped Weak
Khan et al. [present case] 56M with pancreatic adenocarcinoma 1000mg/m2 Two cycles (2 months) CMP/HF No prior history of CHF/CAD 2 months Gemcitabine stopped, partial recovery Strong
  1. CAD, coronary artery disease; F, female; NSCLC, non-small cell lung cancer; NSTEMI, non-ST elevation myocardial infarction; VT, ventricular tachycardia; M, male; SVT, supraventricular tachycardia; AVNRT, AV nodal re-entrant tachycardia; NK, not known; AF, atrial fibrillation; HF, heart failure; CMP, cardiomyopathy; CHF, congestive heart failure.